Primary ovarian insufficiency: a toolkit for the busy clinician.
Journal
Menopause (New York, N.Y.)
ISSN: 1530-0374
Titre abrégé: Menopause
Pays: United States
ID NLM: 9433353
Informations de publication
Date de publication:
12 Dec 2023
12 Dec 2023
Historique:
medline:
12
12
2023
pubmed:
12
12
2023
entrez:
12
12
2023
Statut:
aheadofprint
Résumé
Primary ovarian insufficiency (sometimes known as premature ovarian insufficiency) is a result of loss of ovarian follicular activity before the age of 40 years. It is an endocrine deficiency state in women, characterized by premature estrogen deprivation. In the absence of estrogen replacement, women experience bothersome menopause symptoms and a predisposition to accelerated aging and multimorbidity accumulation. Unless a true contraindication exists, estrogen therapy is recommended at least until the age of natural menopause. This Practice Pearl summarizes the clinical manifestations, diagnostic evaluation, and management of primary ovarian insufficiency.
Identifiants
pubmed: 38086010
doi: 10.1097/GME.0000000000002275
pii: 00042192-990000000-00269
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2023 by The Menopause Society.
Références
Panay N, Anderson R, Nappi R, et al. Premature ovarian insufficiency: an International Menopause Society White Paper. Climacteric 2020;23:426–446. doi: 10.1080/13697137.2020.1804547
doi: 10.1080/13697137.2020.1804547
Golezar S, Ramezani Tehrani F, Khazaei S, Ebadi A, Keshavarz Z. The global prevalence of primary ovarian insufficiency and early menopause: a meta-analysis. Climacteric 2019;22:403–411. doi: 10.1080/13697137.2019.1574738
doi: 10.1080/13697137.2019.1574738
Stuenkel CA, Gompel A. Primary ovarian insufficiency. N Engl J Med 2023;388:154–163. doi: 10.1056/NEJMcp2116488
doi: 10.1056/NEJMcp2116488
Lambrinoudaki I, Paschou SA, Lumsden MA, et al. Premature ovarian insufficiency: a toolkit for the primary care physician. Maturitas 2021;147:53–63. doi: 10.1016/j.maturitas.2020.11.004
doi: 10.1016/j.maturitas.2020.11.004
Singer D, Mann E, Hunter MS, Pitkin J, Panay N. The silent grief: psychosocial aspects of premature ovarian failure. Climacteric 2011;14:428–437. doi: 10.3109/13697137.2011.571320
doi: 10.3109/13697137.2011.571320
NICE Guideline [NG23]: Menopause diagnosis and management. Updated December 5, 2019. Available from: www.nice.org.uk/guidance/ng23. Accessed August 31, 2023.
Webber L, Davies M, Anderson R, et alEuropean Society for Human Reproduction and Embryology (ESHRE) Guideline Group on POI. ESHRE guideline: management of women with premature ovarian insufficiency. Hum Reprod 2016;31:926–937. doi: 10.1093/humrep/dew027
doi: 10.1093/humrep/dew027
“The 2022 Hormone Therapy Position Statement of The North American Menopause Society” Advisory Panel. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause 2022;29:767–794. doi: 10.1097/GME.0000000000002028
doi: 10.1097/GME.0000000000002028
Kaunitz AM, Kapoor E, Faubion S. Treatment of women after bilateral salpingo-oophorectomy performed prior to natural menopause. JAMA 2021;326:1429–1430. doi: 10.1001/jama.2021.3305
doi: 10.1001/jama.2021.3305
Davis SR, Baber R, Panay N, et al. Global consensus position statement on the use of testosterone therapy for women. J Clin Endocrinol Metab 2019;104:4660–4666. doi: 10.1210/jc.2019-01603
doi: 10.1210/jc.2019-01603